🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effectiveness of Introducing Ultra-High B-Value Diffusion-Weighted Imaging as a Modified Abbreviated Protocol for Breast Cancer Detection

Recruitingn/aAges 30 Years - 50 YearsFemaleAin Shams University
NCT06970288 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The aim of this study is to evaluate the added value of non-contrast abbreviated MRI protocol featuring ultra-high B value Diffusion Weighted Imaging to detect, characterize suspicious breast lesions and avoid using contrast.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * • Women with suspicious breast mass (BIRADS 4a) * High risk women (Positive family history) * Women with suspicious axillary lymph nodes by Ultrasound * Women with dense breasts coming for MRI imaging. Exclusion Criteria: * • Contraindications to MRI * Pacemaker, cochlear implant, claustrophobia, ocular implants * Contraindications to contrast administration: * Elevated kidney functions * Women who haven't undergone reliable Mammogram \& Ultrasound * Women with prior treatment or intervention (e.g. biopsy) * Patients' refusal.
💊

What it tests

  • Not listed
📍

Where

1 site
Ain Shams University
Cairo, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy